Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 9, 2026 20:02 UTC |
Schonharting FlorianDirector
|
GrantShare Options (Right to Buy) · Derivative | 2,303 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001140361-26-036052 · form4.xml · derivative · entry 1 Schonharting Florian · CIK 0001360509 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,303 Underlying: Ordinary Shares · 2,303 shares Expires 2033-09-08 F1 · derivative.exercise_date: The share options are immediately fully vested, but are not exercisable until September 8, 2028. Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 20:59 UTC |
Moore DuncanDirector
|
GrantShare Options (Right to Buy) · Derivative | 2,202 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001140361-26-032856 · form4.xml · derivative · entry 1 Moore Duncan · CIK 0001888265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,202 Underlying: Ordinary Shares · 2,202 shares Expires 2033-08-11 F1 · derivative.exercise_date: The share options are immediately fully vested, but are not exercisable until August 11, 2028. Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 20:46 UTC |
Hanley Dermot JohnDirector
|
GrantShare Options (Right to Buy) · Derivative | 2,202 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001140361-26-032846 · form4.xml · derivative · entry 1 Hanley Dermot John · CIK 0002126832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,202 Underlying: Ordinary Shares · 2,202 shares Expires 2033-08-11 F1 · derivative.exercise_date: The share options are immediately fully vested, but are not exercisable until August 11, 2028. Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 20:41 UTC |
Forer MichaelDirector
|
GrantShare Options (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001140361-26-032843 · form4.xml · derivative · entry 2 Forer Michael · CIK 0002126827 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires 2033-08-11 F2 · derivative.exercise_date: The share options vest and become exercisable with respect to 25% on August 11, 2027 and with respect to the remaining 75% in equal monthly installments for three years thereafter. Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 20:41 UTC |
Forer MichaelDirector
|
GrantShare Options (Right to Buy) · Derivative | 2,202 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001140361-26-032843 · form4.xml · derivative · entry 1 Forer Michael · CIK 0002126827 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,202 Underlying: Ordinary Shares · 2,202 shares Expires 2033-08-11 F1 · derivative.exercise_date: The share options are immediately fully vested, but are not exercisable until August 11, 2028. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.